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A B S T R A C T
Background
People with supraventricular tachycardia (SVT) frequently are symptomatic and present to the emergency department for treatment.
Although vagal manoeuvres may terminate SVT, they often fail, and subsequently adenosine or calcium channel antagonists (CCAs)
are administered. Both are known to be effective, but both have a signiﬁcant side effect proﬁle. This is an update of a Cochrane review
previously published in 2006.
Objectives
To review all randomised controlled trials (RCTs) that compare effects of adenosine versus CCAs in terminating SVT.
Search methods
We identiﬁed studies by searching CENTRAL, MEDLINE, Embase, and two trial registers in July 2017. We checked bibliographies
of identiﬁed studies and applied no language restrictions.
Selection criteria
We planned to include all RCTs that compare adenosine versus a CCA for patients of any age presenting with SVT.
Data collection and analysis
We used standard methodological procedures as expected by Cochrane. Two review authors independently checked results of searches
to identify relevant studies and resolved differences by discussion with a third review author. At least two review authors independently
assessed each included study and extracted study data. We entered extracted data into Review Manager 5. Primary outcomes were rate
of reversion to sinus rhythm and major adverse effects of adenosine and CCAs. Secondary outcomes were rate of recurrence, time to
reversion, and minor adverse outcomes. We measured outcomes by calculating odds ratios (ORs) and assessed the quality of primary
outcomes using the GRADE approach through the GRADEproGDT website.
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Main results
We identiﬁed two new studies for inclusion in the review update; the review now includes seven trials with 622 participants who
presented to an emergency department with SVT. All included studies were RCTs, but only three described the randomisation process,
and none had blinded participants, personnel, or outcome assessors to the intervention given. Moderate-quality evidence shows no
differences in the number of people reverting to sinus rhythm who were treated with adenosine or CCA (89.7% vs 92.9%; OR 1.51,
95% conﬁdence interval (CI) 0.85 to 2.68; participants = 622; studies = 7; I2 = 36%). Low-quality evidence suggests no appreciable
differences in major adverse event rates between CCAs and adenosine. Researchers reported only one case of hypotension in the CCA
group and none in the adenosine group (0.66% vs 0%; OR 3.09, 95% CI 0.12 to 76.71; participants = 306; studies = 3; I2 = 0%).
Included trials did not report length of stay in hospital nor patient satisfaction.
Authors’ conclusions
Moderate-quality evidence shows no differences in effects of adenosine and calcium channel antagonists for treatment of SVT on
reverting to sinus rhythm, and low-quality evidence suggests no appreciable differences in the incidence of hypotension. A study
comparing patient experiences and prospectively studied adverse events would provide evidence on which treatment is preferable for
management of SVT.
P L A I N L A N G U A G E S U M M A R Y
Adenosine versus intravenous calcium channel antagonists for tachycardia in adults
Background
Supraventricular tachycardia (SVT) is a common abnormal rhythm of the heart that results in a very rapid heartbeat. This rhythm
problem usually occurs in otherwise healthy people, and common symptoms include palpitations, light-headedness, and chest pain.
Occasionally, SVT may also cause confusion or loss of consciousness. SVT can sometimes be treated with simple physical manoeuvres
such as forced breath holding. When simple manoeuvres fail, SVT can be treated in the emergency department with a variety of drugs.
The two most commonly used drug types are adenosine and calcium channel antagonists (CCAs) (verapamil is the most frequently
used drug in this class).
Study characteristics
This review compares effectiveness and side effects of adenosine and CCAs in terminating SVT episodes. We included in the review
seven trials involving 622 patients. Evidence is current to July 2017.
Key results
Combined analysis of these trials showed no differences between adenosine and CCAs in successfully treating SVT. This ﬁnding is
based on moderate-quality evidence. A temporary drop in blood pressure that did not require treatment was reported in only one of
152 study participants treated with CCAs, and low-quality evidence suggests that no patients treated with adenosine experienced low
blood pressure. We have no data on length of stay in hospital nor on patient satisfaction.
Conclusions
Moderate-quality evidence shows no differences in effects of adenosine and calcium channel antagonists for treatment of SVT on
reverting to sinus rhythm, and low-quality evidence suggests no differences in cases of hypotension. None of these trials examined
patient preferences, which is an important factor in deciding which drug is the ’best’ treatment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Adenosine compared with calcium channel antagonists for supraventricular tachycardia
Patient or population: pat ients with supraventricular tachycardia
Setting: emergency department
Intervention: adenosine
Comparison: calcium channel antagonists (CCAs)
Outcomes Number of
participants
Number
of studies
Odds ratio
(95%CI)
Absolute effects (95% CI) Follow-up Quality of the
evidence
(GRADE)
What happens
With adenosine With CCA Difference
Odds of rever-
sion
622 7 RCTs OR 1.51
(0.85 to 2.68)
89.7% 92.9%
(88.1 to 95.9
3.2%
lower odds of
reversion with
adenosine
(95% CI 1.2
lower to 6.2
lower)
Unt il reversion
occurred
or prede-
term ined maxi-
mum dose was
reached
⊕⊕⊕©
MODERATEa
Higher odds of
reversion indi-
cate better ef -
fect.
Major adverse
event:
hypotension
306 3 RCTs OR 3.09
(0.12 to 76.71)
0.0% 0.0%
(0.0 to 0.0)
0.0% fewer
(0 fewer to 0
fewer)
Up to 2 hours af -
ter infusion
⊕⊕©©
LOWa,b
Lower hypoten-
sion rate indi-
cates fewer ad-
verse events.
Length of stay
in hospital
Not reported 0
Patient sat is-
fact ion
Not reported 0
CI: conf idence interval; OR: odds rat io.
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect,
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aQuality of the evidence downgraded by one level for imprecision. Moderate to wide conf idence intervals.
bQuality of the evidence downgraded by one level for study lim itat ions. Judgements of high risk of bias in all studies, as none
of the studies were blinded.
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B A C K G R O U N D
Description of the condition
Definitions
Supraventricular tachycardia (SVT) includes all tachyarrhythmias
that originate in supraventricular tissue or incorporate supraven-
tricular tissue in the re-entrant circuit and have sudden on-
set and termination. Atrioventricular nodal re-entrant tachycar-
dia (AVNRT) and atrioventricular re-entrant tachycardia (AVRT)
(such as Wolff-Parkinson-White syndrome) are two major types
of SVT; other types include atrial tachycardia, paroxysmal atrial
ﬂutter, and paroxysmal atrial ﬁbrillation (Jayam 2004). Most pa-
tients with SVT due to AVNRT or AVRT do not have associated
structural heart disease (Ferguson 2003).
Epidemiology
SVT is a common arrhythmia with a prevalence of 2 per 1000
adults. The incidence of SVT is 36 per 100,000 people per year,
and women have twice the risk of developing SVT compared with
men (Orejarena 1998).
Clinical presentation and diagnosis
SVTs are often recurrent and occasionally persistent, and are a fre-
quent cause of visits to emergency departments and primary care
physicians’ ofﬁces. Common symptoms of SVT include palpita-
tions, anxiety, light-headedness, chest pain, neck pounding, and
dyspnoea (Delacrétaz 2006; Medi 2009). For patients presenting
with SVT, a 12-lead electrocardiogram (ECG) that shows a nar-
row complex tachycardia is essential for making the diagnosis and
may reveal the mechanism of the arrhythmia.
Treatment
Treatment in stable, symptomatic patients is aimed at terminating
the rhythm by decreasing conduction through the atrioventricular
(AV) node. Increasing vagal tone by the Valsalva manoeuvre or by
carotid sinus massage will effectively revert up to 53% of patients
to sinus rhythm (Wen 1998). Amodiﬁed Valsalvamanoeuvre with
leg elevation and supine positioning can further improve success
(Appelboam 2015). A recent Cochrane review assessed effective-
ness of the Valsalva manoeuvre in terminating SVT and showed a
reversion success rate between 19.4% and 54.3% in two studies.
However, evidence was insufﬁcient overall to support its effective-
ness in terminating SVT (Smith 2015). For patients inwhomvagal
manoeuvres are not effective, calciumchannel antagonists (CCAs),
adenosine, sotalol, beta-blockers, and magnesium sulphate have
been shown to be more effective than placebo (Dougherty 1992;
Gupta 1999; Jordaens 1991; Joshi 1995).However, for acuteman-
agement, adenosine and non-dihydropyridine CCAs - verapamil
and diltiazem - are the intravenous drugs of choice for termina-
tion of SVT (Mangrum 2002). The 2015 American Heart As-
sociation (AHA) Guidelines for Cardiopulmonary Resuscitation
and the 2015 European Resuscitation Council (ERC) Guidelines
for Resuscitation for regular narrow complex SVT recommend
use of adenosine if vagal manoeuvres have failed to terminate the
SVT. CCAs are recommended as a second-line drug if adenosine
is contraindicated or fails to terminate the SVT (Page 2016; Soar
2015). The decision as to which agent should be used is generally
determined by clinician preference, personal experience, and in-
stitutional culture.
Description of the intervention
Adenosine and CCAs have been widely used in SVT with similar
efﬁcacy (Bolton 2000; Delaney 2011). Moreover, the previous
version of this Cochrane review, which compared these agents,
showed no signiﬁcant differences in reversion rate between the two
drugs (Holdgate 2006). However, adenosine is signiﬁcantly more
costly than most intravenous (IV) CCAs.
Adenosine has a half-life of less than a minute, and reversion to
sinus rhythmmay be short-lived, as a subsequent ectopic beat may
reinitiate SVT. Many patients experience short-lived but unpleas-
ant side effects following administration of adenosine, including
dyspnoea, ﬂushing, and, perhaps most dreadfully, a sense of im-
pending death or doom that can be very frightening (Bolton 2000;
Katzung 1995). The recommended adult dosage of adenosine for
peripheral infusion is 6 mg, followed by a 12-mg dose if needed.
Because of the ultrashort duration of action, cumulative effects of
sequential doses are not seen (Ferguson 2003).
On the other hand, CCAs have been used in SVT for many years
and are effective in up to 90% of patients (Bolton 2000; Delaney
2011). Calcium channel blockade causes negative inotropy and
peripheral vasodilation, which may result in hypotension, particu-
larly amongpatientswith impaired left ventricular function. CCAs
have a relatively long half-life of three to six hours, thus adverse
effects may be prolonged. They are relatively contraindicated in
patients who are already taking beta-blockers, as the combined
effect may lead to signiﬁcant bradycardia (Katzung 1995). The
recommended dosage of verapamil is 5 mg IV over 2 minutes,
followed in 5 to 10 minutes by a second dose of 5 to 7.5 mg. The
recommended dosage of diltiazem is 20 mg, followed, if necessary,
by a second dose of 25 to 35 mg; SVT termination should occur
within 5 minutes of infusion completion (Ferguson 2003).
How the intervention might work
Both adenosine and CCAs inhibit conduction through the AV
node, which facilitates termination of SVT. Adenosine is an
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endogenous nucleoside that acts by inhibiting cyclic adenosine
monophosphate (cAMP)-mediated calcium inﬂux and enhanc-
ing potassium conduction. This leads to inhibition of AV nodal
conduction and expansion of the AV nodal refractory period. In
contrast, CCAs act by blocking voltage-dependent calcium chan-
nels, thus reducing intracellular calcium and leading to blockade
of calcium-dependent conduction through the AV node (Katzung
1995).
Why it is important to do this review
The previous version of this review showed that adenosine and
CCAs are reasonably effective but have a signiﬁcant side effect
proﬁle (Holdgate 2006). This review update looks at new studies
conducted over the past 10 years and aims to further explore un-
certainty while helping clinicians and decision makers to regulate
the choice between adenosine and CCAs. Recent American and
British guidelines recommend adenosine as ﬁrst pharmacological
treatment for stable patients with SVT after vagal manoeuvres are
attempted (Blomstrom-Lundqvist 2003; Page 2016; Resuscitation
Council (UK) 2015).
O B J E C T I V E S
To review all randomised controlled trials (RCTs) that compare
effects of adenosine versus CCAs in terminating SVT.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include RCTs. We excluded studies reported to
be randomised but exhibiting major violations in randomisation
methods or treatment allocation, or major differences in baseline
characteristics unlikely to have occurred by chance (Athar 2013;
Riaz 2012). We contacted authors of studies with protocol viola-
tions or for whom we had questions regarding the randomisation
process or approval. We excluded these studies from the analysis
until we receive further information.
Types of participants
We included patients of any age with SVT diagnosed on 12-lead
ECG within 24 hours of onset.
We excludedRCTs of patients with an SVT induced in the electro-
physiology lab, as they do not meet the aim of this review, which
focuses on SVT (see Differences between protocol and review sec-
tion).
Types of interventions
We included all interventions that directly compare any intra-
venous CCA (e.g. verapamil, diltiazem) versus IV adenosine, at
any dosage or infusion rate of either drug.
Types of outcome measures
Primary outcomes
1. Reversion to sinus rhythm
2. Major adverse events (deﬁned as cardiac arrest, prolonged
hypotension, symptomatic bradycardia requiring treatment, and
acute cardiac failure)
Secondary outcomes
1. Time to immediate reversion to sinus rhythm
2. Rate of relapse to SVT within two hours following reversion
3. Length of stay in hospital
4. Minor adverse events (deﬁned as any reported adverse
events other than those deﬁned above)
5. Patient satisfaction as measured on any validated scale
Search methods for identification of studies
Electronic searches
We updated searches conducted in 2006 for the original review
(Appendix 1) by searching the following databases on 5 July 2017
for relevant RCTs (Appendix 2).
1. Cochrane Central Register of Controlled Trials
(CENTRAL), in the Cochrane Library (2017; Issue 6 of 12).
2. Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, MEDLINE Daily, and MEDLINE (Ovid, 1946 to 5
July 2017).
3. Embase (Ovid, 1980 to 2017 Week 27).
We applied the sensitivity-maximising version of the Cochrane
RCT ﬁlter to our MEDLINE search, and we applied terms as
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions to our Embase search (Lefebvre 2011). We imposed
no restrictions on date or language of publication.
Searching other resources
We searched the following sources.
1. Reference lists of relevant identiﬁed publications.
2. Two databases of ongoing trials- ClinicalTrials.gov (
www.clinicaltrials.gov) and the World Health Organization
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(WHO) International Clinical Trials Registry Platform (ICTRP)
(apps.who.int/trialsearch/) - on 7 July 2017 (Appendix 2).
Data collection and analysis
Selection of studies
Two review authors (MQ and AS) independently screened titles
and abstracts for inclusionof all eligible studies identiﬁed as a result
of the search and coded them as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. For disagreements, we asked a
third review author (SA) to arbitrate. We retrieved full-text study
reports/publications; two review authors (MQ and AS) indepen-
dently screened the full texts and identiﬁed studies for inclusion,
or recorded reasons for exclusion of ineligible studies. We resolved
disagreements through discussion or through consultation with a
third review author (SA). We identiﬁed and excluded duplicates
and collated multiple reports of the same study, so that each study
rather than each report was the unit of interest in the review. We
recorded the selection process in sufﬁcient detail and completed
a PRISMA ﬂow diagram and Characteristics of excluded studies
tables.
We excluded all publications that were reviews, retrospective stud-
ies, or studies of observational design, as well as those that were
not randomised, or did not focus on adenosine or CCAs or SVT.
Data extraction and management
Four review authors (MQ, AS, EA, and TJAC) extracted data for
the eligible studies so that each eligible study was independently
extracted by two authors. We extracted and collated data using
a standardised, agreed upon data extraction form. Data collected
include:
1. general information: publication type; title, authors, source,
country, year of publication, trial dates, additional publications;
2. trial characteristics: design, setting, duration, types of
interventions, types of outcome measures, aim of study,
randomisation (and method), allocation concealment (and
method), blinding (outcome assessors), check of blinding,
funding/conﬂict of interest;
3. participants: unit of allocation, method of recruitment,
inclusion criteria, exclusion criteria, total number and numbers
in comparison groups, sex/age, ethnicity, severity of illness,
subgroups reported, similarity of groups at baseline,
withdrawals/losses to follow-up;
4. intervention: dosage, delivery, timing, administration rate,
type of CCA, length of intervention, co-interventions, costs,
compliance;
5. outcomes: outcomes as speciﬁed above, the main outcome
assessed in the study, other events, length of follow-up; and
6. results: for outcomes assessed.
’Summary of findings’ table
We used the GRADE approach, adopted by Cochrane, to inter-
pret ﬁndings (Schünemann 2011). We used the GRADE proﬁler
website (www.gradepro.org) to create a ’Summary of ﬁndings’ ta-
ble. Two review authors (SA, AS) independently assessed the qual-
ity of included studies.
With GRADEproGDT (GRADEproGDT 2015), evidence rela-
tive to each speciﬁc outcome is rated as having high,moderate, low,
or very low quality. We started rating outcomes of all randomised
trials as high quality and downgraded them depending on limita-
tions in study design or execution, indirectness of evidence, unex-
plained heterogeneity, imprecision of results, and high probability
of publication bias. By using GRADEproGDT, we produced a
’Summary of ﬁndings’ table to show outcome-speciﬁc ratings and
to present information about the overall quality of evidence.
We selected all primary outcomes for inclusion in the ’Summary
of ﬁndings’ table. In addition, we had planned to include length
of stay in hospital and patient experience as patient-relevant out-
comes, but included studies did not report this information.
Assessment of risk of bias in included studies
For this updated review, two review authors (MQ, AS, EA, and
TJAC) independently carried out risk of bias assessment.
We assessed risk of bias of included trials, using the methods de-
tailed inChapter 8 of theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We rated the risk of selection bias
by assessing randomisation and allocation concealment. We rated
performance, detection, and attrition bias by assessing blinding to
treatment, blinding to outcome assessment, and losses to follow-
up.We planned to assess selective reporting bias by cross-checking
study outcomes against published protocols or trial registrations.
We coded each risk of bias criterion as having high risk, low risk, or
unclear risk of bias, and we resolved disagreements by discussion.
When necessary, we contacted study authors to try to clarify trial
methods.
Measures of treatment effect
We followed the recommendations provided in the Cochrane
Handbook for Systematic Reviews of Interventions, Sections 9.2 and
9.4, for measuring effects of different data types (Higgins 2011).
For continuous outcomes (e.g. time to reversion), we calculated
mean differences (MDs) and 95% conﬁdence intervals (CIs), and
for dichotomous outcomes (e.g. odds of reversion, adverse events),
we calculated odds ratios (ORs) and 95% CIs.
Unit of analysis issues
Our unit of analysis was the participant. For cross-over trials, we
included only data from the pre-cross-over phase, as time between
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drugs was short and did not allow drug washout. We did not
encounter any cluster-randomised trials.
Dealing with missing data
When possible, we extracted data relevant to intention-to-treat
analyses.
Assessment of heterogeneity
We analysed statistical heterogeneity by visually inspecting the for-
est plot and carrying out both Chi2 and I2 tests, as recommended
in Chapter 9.5.2 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). For the Chi2 test on N-1 degrees
of freedom, we deﬁned P < 0.1 as showing substantial heterogene-
ity. We used the I2 statistic to quantify statistical inconsistency
and to assess the impact of heterogeneity on the meta-analysis. We
determined that I2 > 50% demonstrated high heterogeneity.
If no heterogeneity was present, we performed analysis using a
ﬁxed-effect model. When we detected substantial heterogeneity,
we investigated possible sources of heterogeneity (e.g. study qual-
ity, outcome measures, participants, interventions). When the
source of heterogeneity could not be explained, we did not com-
bine study results.
Assessment of reporting biases
To assess the risk of publication bias, we had planned to construct
funnel plots for each outcome with at least 10 trials; however, this
was not possible owing to the limited number of included studies
(Sterne 2011).
Data synthesis
We used Review Manager 5 software to perform data analysis
(RevMan 5.3).
Subgroup analysis and investigation of heterogeneity
We planned subgroup analysis based on participant age, gender,
duration of symptoms, intercurrent drug therapy, presence of un-
derlying heart disease, prior treatments, and drug dosage to explore
different effects amongst different groups. However, we found in-
sufﬁcient data to carry out these subgroup analyses.
Sensitivity analysis
We had planned to conduct sensitivity analyses on the primary
outcomes to re-analyse exclusion of studies that we judged to be
at high risk of bias across one or more domains of the Cochrane
’Risk of bias’ tool. This was not possible, as all included studies
had at least one domain with high risk of bias.
R E S U L T S
Description of studies
Results of the search
We identiﬁed 237 new references in our updated literature review.
We screened 192 records on the basis of title and abstract after
removing duplicates. We excluded most studies on abstract review
because theywere not RCTs or did not compare adenosine versus a
CCA.We assessed eight full-text records and included two studies
(Lim 2009; Vranic 2006). Figure 1 shows a ﬂow chart of the
updated search.
8Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
We found no trials from reference checking and no ongoing trials
upon searching ClinicalTrials.gov and the International Clinical
Trials Registry Platform.
The original review included eight trials (Cabrera-Sole 1989;
Cheng 2003; DiMarco 1990; Ferreira 1996; Gil Madre 1995;
Greco 1982; Hood 1992; Kulakowski 1998). In this updated re-
view, we excluded three of these, as they included patients with
induced SVT (DiMarco 1990; Hood 1992; Kulakowski 1998).
See Differences between protocol and review for clariﬁcation.
Included studies
Study designs
Four studies included a cross-over component in which the al-
ternate study drug was administered if the ﬁrst drug was unsuc-
cessful (Lim 2009; Ferreira 1996; Gil Madre 1995; Greco 1982).
The authors of one study did not report results after cross-over
but counted them as showing failure of the initial treatment in-
tervention (Lim 2009). Otherwise, we included only data from
the pre-cross-over phase, as time between drugs was short and
did not allow drug washout (particularly for verapamil). Another
study included a third treatment arm given digitalis and did not
provide data from this component of the trial (Greco 1982). The
Lim trial,divided the CCA arm into verapamil and diltiazem (Lim
2009). We combined these arms in a single CCA group for the
purposes of our meta-analysis.
The other three included studies reported that they were ran-
domised and provided no further explanation (Cabrera-Sole 1989;
Cheng 2003; Vranic 2006).
None of the included studies attempted blinding of participants
or personnel.
Study design characteristics of the included studies can be found
in the Characteristics of included studies tables.
Participants
The seven included trials were conducted in six different coun-
tries, were published between 1982 and 2009, and included 622
participants (Cabrera-Sole 1989; Cheng 2003; Ferreira 1996; Gil
Madre 1995; Greco 1982; Lim 2009; Vranic 2006). All studies
but one were conducted in adults (Greco 1982). Inclusion criteria
for one trial included people above the age of 10. However, it was
not possible to determine how many children younger than 18
were included in this trial (Lim 2009).
All included studies enrolled patients with SVT only.
Interventions
Four trials used adenosine in the form of ATP (adenosine triphos-
phate) (Cabrera-Sole 1989; Ferreira 1996; GilMadre 1995; Greco
1982); the remainingﬁve used adenosine. ATP is rapidly converted
to adenosine (the free base form) following exogenous adminis-
9Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
tration; 10 mg ATP is equipotent to 6 mg adenosine, and a linear
dosage relationship has been noted between these two forms of the
drug (Belhassen 1984; Faulds 1991). Verapamil was theCCA used
in all trials. One trial included an arm of diltiazem that was anal-
ysed with verapamil in a combined CCA group (Lim 2009). One
trial administered adenosine in doubling doses (3 mg-6 mg-12
mg), and another used dosing starting at 10 mg ATP (equivalent
to 6mg adenosine) followed by 20 mg ATP (Cheng 2003; Ferreira
1996). Two trials gave adenosine 6 mg IV bolus followed by 12
mg IV bolus if SVT was not reverted with the ﬁrst bolus (Lim
2009; Vranic 2006).
Cheng 2003, Ferreira 1996, and Gil Madre 1995 gave verapamil
in 5-mg boluses. Cheng 2003 gave a 5-mg verapamil infusion over
ﬁve minutes, Gil Madre 1995 in three minutes, Riaz 2012a in
two minutes, and Ferreira 1996 in one minute. One trial did not
specify whether the 5-mg verapamil bolus was infused over time
or was given as an injection (Vranic 2006).
Verapamil was given at a ﬁxed dose of 10 mg in Cabrera-Sole
1989. Another trial administered adenosine by slow intravenous
infusion at a rate of 1 mg per minute up to a maximum dose of
20 mg while assessing the rhythm every two minutes (Lim 2009).
One trial administered diltiazem by slow intravenous infusion at a
rate of 2.5 mg per minute up to a maximum dose of 50 mg, while
assessing the rhythm every two minutes (Lim 2009).
Outcomes
All trials reported reversion to sinus rhythm as the main out-
come. Researchers reported continuous ECGmonitoring or ECG
recording in Cheng 2003, Gil Madre 1995, Greco 1982, and
Vranic 2006. Infusions were given until successful conversion to
sinus rhythm occurred without further details on how this was
assessed in Cabrera-Sole 1989, Ferreira 1996, and Lim 2009. In-
vestigtors in all included studies monitored heart rate and blood
pressure throughout infusion.
No studies reported length of stay in hospital nor outcomes derived
from patient satisfaction surveys.
Excluded studies
We excluded ﬁve studies after acquiring full texts (Athar 2013;
Gill 2014; Riaz 2012; Shaker 2015; Turkoglu 2009).
Riaz 2012 mentions randomisation only in the title and provides
no further explanation in theMethods section.We contacted study
authors for further clariﬁcation. This study mentions that a lot-
tery method was used as the allocation method without providing
further explanation about what this involved. When contacted,
study authors described potentially signiﬁcant differences in base-
line characteristics (four-year difference in age and no P for com-
parison) and explained that no other baseline comparisons were
available). We deemed that this trial did not use an appropriate
randomisation method and therefore excluded it from this review.
Athar 2013 reports a quasi-experimental trial, with participants
“randomly” allocated to two groups. However, study authors did
not conceal allocation, as randomised participants received the
alternate study drug (rather than the allocated drug) if they had a
personal preference for the other drug owing to previous exposure.
This article makes no further mention and provides no details of
randomisation; multiple attempts to contact study authors were
met with no response for clariﬁcation.
Gill 2014 makes no mention of randomisation; our attempts to
contact study authors for clariﬁcation resulted in no response.
Shaker 2015 was an RCT that compared IV adenosine versus
IV adenosine and oral verapamil. Turkoglu 2009 enrolled only
participants with induced SVT.
We excluded three studies that were initially included in the origi-
nal review, as they enrolled patients with induced SVT (DiMarco
1990; Hood 1992; Kulakowski 1998). See Differences between
protocol and review for clariﬁcation.
We have provided study design characteristics of all excluded stud-
ies in the Characteristics of excluded studies tables.
Risk of bias in included studies
For details on risk of bias in included studies, see ’Risk of bias’
tables (Characteristics of included studies). We have presented
information on overall risk of bias in Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
Two trials described the randomisation process (Greco 1982; Lim
2009). Investigators used a random numbers table to allocate par-
ticipants to treatment in Greco 1982. A nurse drawing a serialised
sealed envelope performed randomisation In Lim 2009. All in-
cluded studies provided data showing that participants in both
drug groups were of similar age and had similar physiological pa-
rameters at the time of enrolment.
Allocation concealment
Only one trial reported adequate allocation concealment using
an envelope method (Lim 2009). The remaining six trials did
not provide sufﬁcient information to reveal whether allocation
concealment was adequate.
Blinding
We rated blinding as introducing high risk of bias in all included
studies, as none reported blinding of participants, caregivers, out-
come assessors, or investigators. As these two drugs are usually
given by different methods (adenosine as a rapid bolus, and CCAs
as a slower IV infusion), it would be possible to achieve blinding
only by using a double-dummymethod, which would require sub-
stantial resources. However, no investigators discussed this issue.
Incomplete outcome data
Trialists applied all interventions and assessed all outcomes in the
emergency department during admission of patients. All studies
reported outcomes for all included patients and reported no with-
drawals or dropouts; therefore we rated risk of attrition bias as low
for all studies.
Selective reporting
No protocols for included studies were available for cross-check-
ing of reported study outcomes versus published protocols. All
included trials described outcomes in the Methods sections.
We found a prospective trial registration in clinicaltrials.gov for
Lim2009. Planned outcomes included conversion to sinus rhythm
as a primary outcome, and recurrence of SVT and vital signs as
secondary outcomes. Trial authors reported these outcomes in the
published article.
Other potential sources of bias
Inclusion and exclusion criteria
All trials described inclusion criteria, although most studies stated
that a diagnosis of SVT was the main inclusion criterion without
deﬁning SVT by rate or QRS width, and provided no time limit
on duration of symptoms. All but one study described exclusion
criteria well (Cabrera-Sole 1989).
Publication bias
A funnel plot was not appropriate for assessment of publication
bias, as this review includes fewer than 10 studies (Sterne 2011).
Conflicts of interest and funding
Only one study included a declaration of interests and reported
its source of ﬁnancial support (Lim 2009). Trial authors reported
the absence of any conﬂicts of interests and receipt of funding
from the Department of Clinical Research of Singapore General
Hospital for costs of adenosine and diltiazem.
Effects of interventions
See: Summary of findings for the main comparison Adenosine
compared with calcium channel antagonists for supraventricular
tachycardia
Odds of reversion
All seven studies reported odds of reversion or ’efﬁcacy’ of adeno-
sine versus CCA as an outcome measure, noting no difference in
the odds of reversion to sinus rhythm among participants treated
with adenosine or CCA (Analysis 1.1: 89.7% vs 92.9%; odds ra-
tio (OR) 1.51, 95% conﬁdence interval (CI) 0.85 to 2.68; par-
ticipants = 622; studies = 7; I2 = 36%). This result is based on
evidence of moderate quality (Summary of ﬁndings for the main
comparison).
Low heterogeneity between trials can be explained by differences
in doses of adenosine and verapamil given. All but one study
used sequentially increasing doses of each trial drug until rever-
sion occurred or the predetermined maximum dose was reached,
whichever occurred ﬁrst (Cabrera-Sole 1989). Six trials reported
odds of reversion as overall cumulative reversion for participants
who received one or more doses of each drug. Trialists in one study
used a ﬁxed dose of each drug with no escalation of drug dosage
in the absence of reversion (Cabrera-Sole 1989).
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Major adverse events
Three trials reported outcomes of hypotension, noting only one
episode of hypotension with CCA and none with adenosine
(Analysis 1.5: 0.66% vs 0%; OR3.09, 95%CI 0.12 to 76.71; par-
ticipants = 306; studies = 3; I2 = 0%) (Cabrera-Sole 1989; Ferreira
1996; Lim 2009). This result is not precise, and the conﬁdence
interval is wide. These results are based on evidence of low quality
(Summary of ﬁndings for the main comparison).
Two of the three trials reporting hypotension speciﬁcally excluded
patients with systolic blood pressure (BP) < 90 mmHg at enrol-
ment. A hypotensive episode in one trial occurred at infusion of
7.5 mg of verapamil and did not require speciﬁc treatment (Lim
2009).
Only one study speciﬁcally reported absence of major bradycardia
in either group (Ferreira 1996). No studies reported acute heart
failure.
The only paediatric study reported that two participants expe-
rienced cardiac arrest after receiving treatment with verapamil
(Greco 1982). One was an infant with cyanotic heart disease and
electrolyte disturbances, the other was an infant already receiv-
ing treatment with a beta-blocker forWolff-Parkinson-White syn-
drome. Both children were successfully resuscitated.
Time to reversion
Average time to reversion was reported in four studies (Cheng
2003; Ferreira 1996; Lim 2009; Vranic 2006). Each study showed
a statistically signiﬁcantly shorter time to reversion with adenosine
than with verapamil. Average time to reversion in all studies com-
bined was 44 seconds for adenosine and 394 seconds for CCAs.
Very high heterogeneity between studies made pooling of results
inappropriate. This heterogeneity may be due to differences in
timing and dosing protocols between trials. Cheng 2003 reported
’average time after dose’; trialists did not report how time to re-
version was estimated in two trials (Lim 2009; Vranic 2006).
Relapse rate
Four studies reported rate of relapse to SVT following reversion
to sinus rhythm (Ferreira 1996; Gil Madre 1995; Lim 2009;
Vranic 2006). Results show no differences in relapse rates between
adenosine and CCAs (Analysis 1.3: 3.3% vs 1.14%; OR 0.38,
95% CI 0.09 to 1.69; participants = 358; studies = 4; I2 = 0%).
Two studies reported the period of observation following drug
administration as 2 hours and 24 hours, respectively (Lim 2009;
Vranic 2006). Ferreira 1996 reported relapse at 10 minutes for one
participant given adenosine but did not mention time to relapse
for the other participant given verapamil.
Length of stay in hospital
None of the included studies reported this outcome.
Minor adverse events
Studies reported numbers of speciﬁc adverse events rather than
numbers of participants experiencing minor adverse events. Re-
ported minor adverse events included chest tightness, nausea,
shortness of breath, headache, and ﬂushing. As patients might ex-
perience several different minor adverse events, double counting
and exaggeration of estimated effects may occur. Therefore, we
have not provided a total pooled estimate of minor adverse event
subgroups.
Three trials reported that chest tightness occurred more frequently
among participants treated with adenosine compared with ver-
apamil (Analysis 1.4.1: 11.7% vs 0%; OR 0.09, 95% CI 0.02
to 0.50; participants = 222; studies = 3; I2 = 0%) (Cheng 2003;
Ferreira 1996; Gil Madre 1995).
Two trials reported shortness of breath, noting no differences be-
tween adenosine and CCAs (Analysis 1.4.2: 6.9% vs 1.2%; OR
0.23, 95% CI 0.04 to 1.37; participants = 171; studies = 2; I2 =
0%) (Cheng 2003; Gil Madre 1995). These trials also reported
nausea and headache, but high heterogeneity for these outcomes
made pooling of results inappropriate.
Flushing as reported in trial was higher in the adenosine group
(Analysis 1.4.3: 61.5% vs 0%; OR 0.01, 95% CI 0.00 to 0.24;
participants = 50; studies = 1; I2 = 0%) (Gil Madre 1995).
Greco 1982 also reported nausea, chest tightness, shortness of
breath, and headache at higher rates among participants treated
with adenosine. However, data included results from a non-ran-
domised component of the study; therefore, we did not include
these outcomes in the pooled analysis.
Two trials did not report any minor adverse events (Lim 2009;
Vranic 2006).
Patient satisfaction
None of the included studies reported this outcome.
Subgroup analysis
We found insufﬁcient data to carry out intended subgroup analy-
ses.
Sensitivity analysis
All included studies had one or more component at high risk of
bias; therefore, a sensitivity analysis for studies with low risk of
bias was not possible.
D I S C U S S I O N
Summary of main results
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Adenosine and CCA efficiency
Our review aimed to examine the relative efﬁcacy and safety of
adenosine and calcium channel antagonists (CCAs) for patients
presenting with supraventricular tachycardia (SVT). We included
seven trials with 622 participants.
We used three outcomes to compare efﬁciency of these agents:
odds of reversion, time to reversion, and relapse rates. Reversion
and relapse rates were similar with adenosine and CCAs.We could
not reliably examine time to reversion in a pooled analysis owing
to severe heterogeneity. Time to reversion was on average less than
a minute with adenosine and longer than six minutes with CCAs.
The difference between these two treatments is probably of little
clinical signiﬁcance for patients who are haemodynamically stable.
Adverse effects
Investigators reported only one episode of hypotension among
patients treated with verapamil and none in those treated with
adenosine. Two cardiac arrests occurred in a paediatric study pub-
lished in the 1980s, in clinical circumstances for which current
practice guidelines would not recommend verapamil without ex-
pert consultation (ACLS 2015).
Minor adverse events occurred more frequently with adenosine
and affected approximately one in ten patients. No studies specif-
ically deﬁned minor adverse events. Study authors relied on post
hoc reporting; therefore, it is possible that the actual ratewas higher
than was reﬂected in the data. From a medical perspective, short-
lived symptoms such as chest pain may be perceived as minor;
however, no studies explored patients’ perception of the relative
severity of these events. No study commented on the sense of im-
pending death or doom associated with adenosine treatment.
Patient-centred outcomes
The two outcomes for which we could ﬁnd no data (i.e. patient
satisfaction and length of hospital stay) may be helpful in the
clinical decision as to which treatment should be used. From the
patient’s perspective, the risk of brief but unpleasant side effects,
such as feeling close to death, may be unacceptable.
Overall completeness and applicability of
evidence
The main gap in current knowledge involves patient preference.
None of the included studies reported results on patient experi-
ences.
Quality of the evidence
The GRADE approach shows that the quality of the evidence is
moderate for the odds of reversion outcome (i.e. the result is likely
to be close to the true effect but can be substantially different). The
quality of evidence is low for the outcome of rate of major adverse
events, but this result should be viewed with caution (Summary of
ﬁndings for the main comparison). Reasons for downgrading the
quality of evidence for adverse events were the presence of high
risk of bias in the blinding domain for all included studies and
imprecision of results with wide conﬁdence intervals. As studies
objectively assessed reversion to sinus rhythm using electrocardio-
grams (ECGs), lack of blinding of participants or outcome asses-
sors is not expected to have an impact on this endpoint.
Authors of all seven included studies stated that these were ran-
domised trials; however, randomisation was poorly or incom-
pletely reported. Only two studies speciﬁed how randomisation
was undertaken (Greco 1982; Lim 2009). One study described
allocation concealment (Lim 2009). None of the included studies
were blinded. Most included trials used a cross-over design; how-
ever we have provided only pre-cross-over data in this review.
Potential biases in the review process
Weperformed a comprehensive literature search to ﬁnd all relevant
trials for inclusion in this review. Two review authors indepen-
dently performed the literature search, selected studies, extracted
data, and assessed risk of bias to minimise review bias. We con-
tacted study authors to request further information when needed.
We conducted the review according to the previously published
protocol. However, in some ways, we deviated from the protocol
during the review process. We have documented deviations under
Differences between protocol and review.
Agreements and disagreements with other
studies or reviews
Delaney 2011 is a systematic review and meta-analysis of adeno-
sine versus verapamil for treatment of stable SVT. This review in-
cluded eight studies (Cabrera-Sole 1989; Cheng 2003; DiMarco
1990; Ferreira 1996; Gil Madre 1995; Hood 1992; Kulakowski
1998; Lim 2009). Review authors concluded that both adenosine
and verapamil are effective and safe and included studies with in-
duced SVT that we excluded from our review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with SVT
15Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We found no evidence of differences in effects of adenosine and
calcium channel antagonists (CCAs) for treatment of supraven-
tricular tachycardia (SVT). Our results are based on evidence of
moderate quality.We found that adenosine is associatedwithmore
frequent minor adverse events such as chest pain.
For clinicians
Adenosine is the safer option in clinical situations for which ve-
rapamil is clearly contraindicated, as when people who have hy-
potension and poor left ventricular function are already taking
beta-blockers, when individuals have other tachyarrhythmias such
as broad complex tachycardia, or when a rapid effect is essential
(as in very unstable or highly symptomatic patients). Verapamil is
suggested for patients with asthma, as well as for stable patients in
whom an extra 5 minutes is not likely to result in a worse clinical
outcome, patients treated with adenosine in the past who expe-
rienced uncomfortable side effects that they would rather avoid
if possible, patients who relapsed to SVT shortly after receiving
adenosine because of frequent ectopics, and patients with frequent
atrial or ventricular ectopics that could trigger a new episode of
arrhythmia.
For funders and policy makers
Although current guidelines recommend adenosine as the ﬁrst
treatment choice, we could not conﬁrm its superiority versusCCAs
(Blomstrom-Lundqvist 2003; Page 2016; Resuscitation Council
(UK) 2015). Therefore, future updated versions of these guidelines
might consider the evidence presented in this review.
Implications for research
The main gap in our current knowledge involves which treatment
patients prefer. Studies comparing patient experiences and adverse
events are needed to fully answer whether one treatment is prefer-
able in the management of SVT.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cabrera-Sole 1989
Methods RCT
Participants Age not stated, presumed adult
Gp 1: 44 participants
Gp 2: 43 participants
Inclusion criteria: SVT
Exclusion criteria: not stated
Interventions Gp 1: ATP 20 mg bolus
Gp 2: verapamil 10 mg bolus
Outcomes Reversion rate
Minor A/E
Notes Country: Spain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation performed, but method not speciﬁed
Allocation concealment (selection bias) Unclear risk Information insufﬁcient to determine whether allocation con-
cealment was adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding intervention was made.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up, withdrawals, dropouts, or protocol de-
viations were reported
Selective reporting (reporting bias) Unclear risk No study protocol was available for comparison of intended
study outcomes vs reported outcomes
Other bias Unclear risk No mention of funding and no mention of possible conﬂicts of
interest
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Cheng 2003
Methods RCT
Participants Adults 18 to 75 years
Gp 1: 60 participants (29 M)
Gp 2: 62 participants (25 M)
Inclusion criteria: paroxysmal SVT
Exclusion criteria: heart block; asthma; emphysema; tea/coffee; taking beta-blocker, Ca
antagonist, or other antihypertensive or antiarrhythmics; pregnancy or breastfeeding
Interventions Gp 1: Adenosine 3 mg, then 6 mg, then 9 mg every 1 to 2 minutes if no response to
previous dose. Mean dose 9.63 mg
Gp 2: Verapamil 5 mg over 5 minutes, repeated if no reversion by 15 minutes. Mean
dose 7.15 mg
Outcomes Reversion rate
Time to reversion
Minor A/E
Notes Country: China
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation mentioned, but method not speciﬁed
Allocation concealment (selection bias) Unclear risk Information insufﬁcient to determine whether allocation con-
cealment was adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding intervention was made.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up, withdrawals, dropouts, or protocol de-
viations were reported
Selective reporting (reporting bias) Unclear risk No study protocol was available for comparison of intended
study outcomes vs reported outcomes
Other bias Unclear risk No mention of funding and no mention of possible conﬂicts of
interest
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Ferreira 1996
Methods RCT with cross-over design
Participants Adults
Gp 1: 25 (8 M)
Gp 2: 25 (9 M)
Inclusion criteria: paroxysmal SVT presenting to ED
Exclusion criteria: SBP<90, lowoutput state,CCF,UAP, recentMI, takingdipyridamole
or methylxanthine
Interventions Gp 1: ATP 10 mg, then 20 mg bolus if needed. Mean dose 10.8 mg
Gp 2: Verapamil infused at 5 mg/min up to 15 mg if needed. Mean dose 9.38 mg
Outcomes Reversion rate
Time to reversion
Recurrence rate
Minor A/E
Major A/E
Notes Country: Brazil
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation mentioned, but method not speciﬁed
Allocation concealment (selection bias) Unclear risk Information insufﬁcient to determine whether allocation
concealment was adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding intervention was made.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up, withdrawals, dropouts, or proto-
col deviations were reported
Selective reporting (reporting bias) Unclear risk No study protocol was available for comparison of in-
tended study outcomes vs reported outcomes
Other bias Unclear risk No mention of funding and no mention of possible con-
ﬂicts of interest
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Gil Madre 1995
Methods RCT with cross-over design
Participants Adults (25 M,25 F)
Gp 1: 26 participants
Gp 2: 24 participants
Inclusion criteria: SVT without haemodynamic instability, unresponsive to vagal ma-
noeuvres
Exclusion criteria: SBP < 80, current treatment with beta-blockers or Ca antagonists,
known ventricular dysfunction, asthma, recent treatment with dipyridamole
Interventions Gp 1: ATP 5 mg, then 10 mg, then 20 mg every 1 minute if previous dose not effective
Gp 2: 5 mg over 3 minutes, repeated after 10 minutes if no response to ﬁrst dose
Outcomes Reversion rate
Relapse rate
Minor A/E
Notes Country: Spain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation mentioned, but method not speciﬁed
Allocation concealment (selection bias) Unclear risk Information insufﬁcient to determine whether allocation
concealment was adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding intervention was made.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up, withdrawals, dropouts, or proto-
col deviations were reported
Selective reporting (reporting bias) Unclear risk No study protocol was available for comparison of in-
tended study outcomes vs reported outcomes
Other bias Unclear risk No mention of funding and no mention of possible con-
ﬂicts of interest
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Greco 1982
Methods RCT with cross-over design
Participants Children < 13 years
Gp 1: 20 participants
Gp 2: 23 participants
Inclusion criteria: presentation with paroxysmal SVT
Exclusion criteria: shock or response to vagal manoeuvre
Interventions Gp 1: ATP titrated to effect, mean dose 7.46 mg
Gp 2: verapamil titrated to effect, mean dose 2.09 mg
Outcomes Reversion rate
Minor A/E
Notes Two-part study; only participants in second part included, as no randomisation in ﬁrst
part
Country: Italy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table
Allocation concealment (selection bias) Unclear risk Information insufﬁcient to determine whether allocation
concealment was adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No attempt at blinding intervention was made.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up, withdrawals, dropouts, or proto-
col deviations were reported
Selective reporting (reporting bias) Unclear risk No study protocol was available for comparison of in-
tended study outcomes vs reported outcomes
Other bias Unclear risk No mention of funding and no mention of possible con-
ﬂicts of interest
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Lim 2009
Methods RCT with cross-over design
Participants 233 participants with spontaneous regular narrow complex tachycardia
and failed Valsalva manoeuvres
Gp 1: 104 participants on adenosine, mean age 50.6 ± 17.0, 42% males
Gp 1: 102 participants on verapamil (57 people) and diltiazem (59 people). Mean age
48.9 ± 18.3, 40% males
27 excluded from analysis after enrolment, as they had an arrhythmia other than SVT
Inclusion criteria: at least 10 years of age with regular narrow complex tachycardia and
an electrocardiographic (ECG) diagnosis of SVT, not converted by vagal manoeuvres
(Valsalva manoeuvre or carotid sinus massage or both)
Exclusion criteria: signs of impaired cerebral perfusion (e.g. alteredmental state) or acute
pulmonary oedema
Interventions Gp 1: adenosine, initially a 6-mg bolus, then a 12-mg bolus after 2 minutes, if needed
Gp 2: verapamil and diltiazem
Verapamil: slow intravenous infusion at a rate of 1 mg per minute, up to a maximum
dose of 20 mg
Diltiazem: slow intravenous infusion at a rate of 2.5 mg per minute, up to a maximum
dose of 50 mg
Refractory cases were crossed-over if initial intervention was not successful after repeated
admissions. These caseswere counted as failures of the intervention andwere not included
in the ﬁnal analysis
Outcomes Reversion rate
Relapse rate: recurrences during 2-hour observation period
Major adverse event: hypotension
Notes ED of the Singapore General Hospital
Country: Singapore
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by a nurse who drew a
serialised sealed envelope
Allocation concealment (selection bias) Low risk Participants were randomised with the use of sealed en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Interventions were given by different methods, and no
attempt at blinding intervention was made
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned
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Lim 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Twenty-seven participants were excluded from analysis,
as they were found not to have SVT after enrolment.
Therefore, 15% of participants were not analysed in the
groups to which they were randomised
However, as participants were randomised, excluded pa-
tients were closely distributed across intervention groups
and had similar reasons for exclusion
Selective reporting (reporting bias) Low risk The main outcomes reported are the same as those
planned at a prospective trial registration
Other bias Low risk Study authors declared no conﬂicts of interest. The De-
partment of Clinical Research, Singapore General Hos-
pital, funded adenosine and diltiazem.
Vranic 2006
Methods RCT
Participants Adults with spontaneous SVT or WPW
64 consecutive patients with diagnosis of acute SVT or WPW syndrome
Males 48.4%
Mean age of men was 47 ± 12 years, and women 48 ± 12 years
Inclusion criteria: older than 18 years of age with abrupt onset of SVT lasting 20 to 30
minutes
Exclusion criteria: presence of atrial ﬂutter, asthma or chronic obstructive pulmonary
disease, long-term use of dipyridamole or theophylline derivatives, pregnant or breast-
feeding women, any heart disease apart from coronary artery disease (different forms
of stenotic lesions of major arteries or veins), heart failure or pulmonary heart disease,
history of bleeding diathesis, stroke, hypertension over 200/110 mmHg, severe diseases
of liver or renal function (anamnestic data), conﬁrmed malignancies, severe genetic dis-
eases, severe anaemia, alcohol or narcotic addiction, psychiatric disorders, AV block of
second
or third degree, sick sinus syndrome
Interventions Gp 1: adenosine IV bolus of 6 mg, then 12 mg if needed
Gp 2: verapamil or IV 5 mg up to maximum dose of 10 mg if needed
Outcomes Cardioversion into sinus rhythm
Duration to sinus rhythm conversion
Relapse
Biomarkers outcomes
Notes Intensive care unit and emergency centre at Clinical Center of Serbia
Country: Serbia
Risk of bias
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Vranic 2006 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation and randomisation method not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Interventions given by different methods and no attempt at
blinding intervention made
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk Interventions were applied and outcomes were assessed within
the department. No losses to follow-up, withdrawals, or drop-
outs were reported
Selective reporting (reporting bias) Unclear risk No study protocol was available for comparison of intended
study outcomes vs reported outcomes
Other bias Unclear risk No mention of funding and no mention of possible conﬂicts of
interest
A/E: adverse events.
ATP: adenosine triphosphate.
AV: atrioventricular.
CCF: congestive cardiac failure.
ECG: electrocardiogram.
ED: emergency department.
MI: myocardial infarction.
RCT: randomised controlled trial.
SBP: systolic blood pressure.
SVT: supraventricular tachycardia.
UAP: unstable angina pectoris.
WPW: Wolff-Parkinson-White.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Athar 2013 Not an RCT, as allocation to treatment was changed according to previous patient experience with adenosine/
verapamil. In addition, signiﬁcant differences in baseline characteristics suggest that no appropriate randomisation
method was used. Study authors have not yet replied to our request for further data/information
Ballo 2004 Retrospective chart review and no relevant outcomes measured
Belhassen 1984 Review article, not a trial
Conti 1995 Editorial only
DiMarco 1990 Included participants with induced SVT
Garratt 1989 Not a randomised trial. Participants with induced SVT were given adenosine, then were re-induced and given
verapamil
Gill 2014 Not a randomised trial
Hood 1992 Included participants with induced SVT
Kulakowski 1998 Included participants with induced SVT
Rankin 1991 Review article, not a trial
Riaz 2012 Signiﬁcant differences in baseline characteristics suggest that no appropriate randomisation method was used.
Study authors have not yet replied to our request for further data/information
Sellers 1987 Retrospective chart review
Sethi 1994 Not a randomised trial. Participants with induced SVT were given adenosine, then were re-induced and given
verapamil
Shaker 2015 Comparison of intravenous adenosine vs intravenous adenosine with oral verapamil
Trappe 1997 Comparison of adenosine vs ajmaline (class 1A antiarrhythmic). No calcium antagonist arm included
Turkoglu 1996 Not a randomised trial
Turkoglu 2009 Only participants with induced SVT were included.
RCT: randomised controlled trial.
SVT: supraventricular tachycardia.
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D A T A A N D A N A L Y S E S
Comparison 1. Adenosine vs CCA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Odds of reversion 7 622 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.85, 2.68]
2 Time to reversion (seconds) 4 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Relapse to SVT post reversion 4 358 Odds Ratio (M-H, Fixed, 95% CI) 0.38 [0.09, 1.69]
4 Minor adverse events 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Chest tightness 3 222 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.02, 0.50]
4.2 Shortness of breath 2 171 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.04, 1.37]
4.3 Flushing 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.01 [0.00, 0.24]
5 Hypotension 3 306 Odds Ratio (M-H, Fixed, 95% CI) 3.09 [0.12, 76.71]
Analysis 1.1. Comparison 1 Adenosine vs CCA, Outcome 1 Odds of reversion.
Review: Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia
Comparison: 1 Adenosine vs CCA
Outcome: 1 Odds of reversion
Study or subgroup CCA Adenosine Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cabrera-Sole 1989 39/43 42/44 19.9 % 0.46 [ 0.08, 2.68 ]
Cheng 2003 54/62 52/60 35.2 % 1.04 [ 0.36, 2.97 ]
Ferreira 1996 23/25 24/25 9.9 % 0.48 [ 0.04, 5.65 ]
Gil Madre 1995 20/24 21/26 17.3 % 1.19 [ 0.28, 5.08 ]
Greco 1982 21/23 18/20 8.6 % 1.17 [ 0.15, 9.14 ]
Lim 2009 100/102 90/104 9.0 % 7.78 [ 1.72, 35.16 ]
Vranic 2006 31/31 33/33 Not estimable
Total (95% CI) 310 312 100.0 % 1.51 [ 0.85, 2.68 ]
Total events: 288 (CCA), 280 (Adenosine)
Heterogeneity: Chi2 = 7.76, df = 5 (P = 0.17); I2 =36%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours adenosine Favours CCA
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Analysis 1.2. Comparison 1 Adenosine vs CCA, Outcome 2 Time to reversion (seconds).
Review: Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia
Comparison: 1 Adenosine vs CCA
Outcome: 2 Time to reversion (seconds)
Study or subgroup CCA Adenosine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cheng 2003 62 414.4 (191.2) 60 34.2 (19.5) 380.20 [ 332.35, 428.05 ]
Ferreira 1996 25 248 (152.5) 25 29.6 (11.6) 218.40 [ 158.45, 278.35 ]
Lim 2009 102 397.8 (0) 104 88.8 (0) Not estimable
Vranic 2006 31 514 (229.2) 33 21.5 (2.62) 492.50 [ 411.81, 573.19 ]
-500 -250 0 250 500
Favours verapamil Favours adenosine
Analysis 1.3. Comparison 1 Adenosine vs CCA, Outcome 3 Relapse to SVT post reversion.
Review: Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia
Comparison: 1 Adenosine vs CCA
Outcome: 3 Relapse to SVT post reversion
Study or subgroup CCA Adenosine Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ferreira 1996 1/23 1/24 15.0 % 1.05 [ 0.06, 17.76 ]
Gil Madre 1995 0/20 3/21 53.5 % 0.13 [ 0.01, 2.67 ]
Lim 2009 1/102 2/104 31.5 % 0.50 [ 0.05, 5.66 ]
Vranic 2006 0/31 0/33 Not estimable
Total (95% CI) 176 182 100.0 % 0.38 [ 0.09, 1.69 ]
Total events: 2 (CCA), 6 (Adenosine)
Heterogeneity: Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CCA Favours adenosine
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Analysis 1.4. Comparison 1 Adenosine vs CCA, Outcome 4 Minor adverse events.
Review: Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia
Comparison: 1 Adenosine vs CCA
Outcome: 4 Minor adverse events
Study or subgroup CCA Adenosine Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Chest tightness
Cheng 2003 0/62 3/60 25.0 % 0.13 [ 0.01, 2.60 ]
Ferreira 1996 0/25 5/25 38.2 % 0.07 [ 0.00, 1.40 ]
Gil Madre 1995 0/24 5/26 36.7 % 0.08 [ 0.00, 1.53 ]
Subtotal (95% CI) 111 111 100.0 % 0.09 [ 0.02, 0.50 ]
Total events: 0 (CCA), 13 (Adenosine)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
2 Shortness of breath
Cheng 2003 1/60 3/61 47.0 % 0.33 [ 0.03, 3.24 ]
Gil Madre 1995 0/24 3/26 53.0 % 0.14 [ 0.01, 2.80 ]
Subtotal (95% CI) 84 87 100.0 % 0.23 [ 0.04, 1.37 ]
Total events: 1 (CCA), 6 (Adenosine)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.11)
3 Flushing
Gil Madre 1995 0/24 16/26 100.0 % 0.01 [ 0.00, 0.24 ]
Subtotal (95% CI) 24 26 100.0 % 0.01 [ 0.00, 0.24 ]
Total events: 0 (CCA), 16 (Adenosine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Chi2 = 2.70, df = 2 (P = 0.26), I2 =26%
0.01 0.1 1 10 100
Favours CCA Favours adenosine
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Analysis 1.5. Comparison 1 Adenosine vs CCA, Outcome 5 Hypotension.
Review: Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia
Comparison: 1 Adenosine vs CCA
Outcome: 5 Hypotension
Study or subgroup CCA Adenosine Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cabrera-Sole 1989 0/25 0/25 Not estimable
Ferreira 1996 0/25 0/25 Not estimable
Lim 2009 1/102 0/104 100.0 % 3.09 [ 0.12, 76.71 ]
Total (95% CI) 152 154 100.0 % 3.09 [ 0.12, 76.71 ]
Total events: 1 (CCA), 0 (Adenosine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours CCA Favours adenosine
A P P E N D I C E S
Appendix 1. Search strategy 2006
CENTRAL on the Cochrane Library
#1 ADENOSINE
#2 adenosin*
#3 (#1 or #2)
#4 TACHYCARDIA SUPRAVENTRICULAR
#5 (supraventricular next arrhythmia*)
#6 tachycardia*
#7 tachyarrhythmi*
#8 (idioventricular next rhythm*)
#9 supraventric*
#10 svt
#11 psvt
#12 (#4 or #5 or #6 or #7 or #8 or #9 or #10 or #11)
#13 (#3 and #12)
Ovid MEDLINE search strategy
1 exp Adenosine/
2 adenosin$.tw.
3 1 or 2
4 exp Tachycardia, Supraventricular/
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5 supraventricular tachycardia$.tw.
6 supraventricular arrhythmia$.tw.
7 supraventricular tachyarrhythmi$.tw.
8 sinus tachycardia$.tw.
9 svt.tw.
10 psvt.tw.
11 or/4-10
12 3 and 11
Ovid Embase
1 exp Adenosine/
2 adenosin$.tw.
3 1 or 2
4 Heart Supraventricular Arrhythmia/
5 Supraventricular Tachycardia/
6 Paroxysmal Supraventricular Tachycardia/
7 supraventricular tachycardia$.tw.
8 supraventricular arrhythmia$.tw.
9 supraventricular tachyarrhythmi$.tw.
10 sinus tachycardia$.tw.
11 svt.tw.
12 psvt.tw.
13 or/4-12
14 3 and 13
Appendix 2. Search strategy 2017
CENTRAL
#1 MeSH descriptor Adenosine explode all trees
#2 adenosin*
#3 (#1 OR #2)
#4 MeSH descriptor Tachycardia, Supraventricular explode all trees
#5 tachycardia*
#6 supraventricular next arrhythmia*
#7 tachyarrhythmi*
#8 idioventricular next rhythm*
#9 supraventric*
#10 svt
#11 psvt
#12 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)
#13 (#3 AND #12)
#14 (#13), from 2010 to 2017
MEDLINE
1. exp Adenosine/
2. adenosin$.tw.
3. 1 or 2
4. exp Tachycardia, Supraventricular/
5. supraventricular tachycardia$.tw.
6. supraventricular arrhythmia$.tw.
7. supraventricular tachyarrhythmi$.tw.
8. sinus tachycardia$.tw.
9. svt.tw.
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10. psvt.tw.
11. or/4-10
12. 3 and 11
13. randomized controlled trial.pt.
14. controlled clinical trial.pt.
15. randomized.ab.
16. placebo.ab.
17. drug therapy.fs.
18. randomly.ab.
19. trial.ab.
20. groups.ab.
21. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. exp animals/ not humans.sh.
23. 21 not 22
24. 12 and 23
25. (2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017*).ed.
26. 24 and 25
Embase
1. adenosine/
2. adenosin$.tw.
3. 1 or 2
4. supraventricular tachycardia/
5. heart supraventricular arrhythmia/
6. paroxysmal supraventricular tachycardia/
7. supraventricular tachycardia$.tw.
8. supraventricular arrhythmia$.tw.
9. supraventricular tachyarrhythmi$.tw.
10. sinus tachycardia$.tw.
11. svt.tw.
12. psvt.tw.
13. or/4-12
14. 3 and 13
15. random$.tw.
16. factorial$.tw.
17. crossover$.tw.
18. cross over$.tw.
19. cross-over$.tw.
20. placebo$.tw.
21. (doubl$ adj blind$).tw.
22. (singl$ adj blind$).tw.
23. assign$.tw.
24. allocat$.tw.
25. volunteer$.tw.
26. crossover procedure/
27. double blind procedure/
28. randomized controlled trial/
29. single blind procedure/
30. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. (animal/ or nonhuman/) not human/
32. 30 not 31
33. 14 and 32
34. (2010* or 2011* or 2012* or 2013* or 2014* or 2015* or 2016* or 2017*).dd, em.
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35. 34 and 35
Clinicaltrials.gov and the WHO International Clinical Trials Registry Platform (apps.who.int/trialsearch/)
adenosine And supraventricular tachycardia
WH A T ’ S N E W
Last assessed as up-to-date: 5 July 2017.
Date Event Description
17 July 2017 New citation required and conclusions have changed Exclusion of induced SVT
Included 2 new studies and added GRADEproGDT quality
assessment
5 July 2017 New search has been performed New search
H I S T O R Y
Protocol ﬁrst published: Issue 1, 2005
Review ﬁrst published: Issue 4, 2006
Date Event Description
4 July 2016 New search has been performed Converted to new review format
C O N T R I B U T I O N S O F A U T H O R S
S Alabed: selection of studies, data extraction and analysis, and review writing and editing.
A Sabouni: selection of studies and data extraction.
R Providencia: review editing and clinical expertise.
E Atallah: co-writing of review and data extraction.
M Qintar: review editing, selection of studies, data extraction, and clinical expertise.
T JA Chicho: review editing, data extraction, and clinical expertise.
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D E C L A R A T I O N S O F I N T E R E S T
SA: none known.
AS: none known.
RP: has received a research grant fromMedtronic for a clinical epidemiology study on sudden cardiac death, and proctored and lectured
for Medtronic and Pﬁzer, respectively, on topics related to atrial ﬁbrillation. However, these topics are not directly related to treatment
of supraventricular arrhythmias (which do not include atrial ﬁbrillation) in A&E.
EA: none known.
MQ: none known.
T JA C: none known.
S O U R C E S O F S U P P O R T
Internal sources
• None, Not speciﬁed.
External sources
• National Institute for Health Research (NIHR), UK.
S Alabed currently holds an NIHR Academic Clinical Fellowship (ACF)
• National Institutes of Health (NIH), USA.
M Qintar is supported by The National Heart, Lung, and Blood Institute of the NIH under Award Number T32HL110837
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences between original review in 2006 and update in 2017
The main changes in review methods compared with those used in the original review include the following.
1. Excluding studies of induced SVT: We excluded studies involving induced SVTs as they are not relevant to patients presenting
acutely to the emergency department. Patients with inducible SVT may not necessarily be affected by SVT in their daily life. Induced
SVTs can be terminated with pacing manoeuvres, whereas spontaneous SVTs treated in emergency rooms/A&E may last for hours
and may require IV treatment for control.
2. Excluding quasi-randomised trials: Although the review protocol mentioned inclusion of quasi-RCTs, we decided to exclude
trials with major violations in randomisation methods or treatment allocation. We also excluded studies reported to be randomised
but showing no data on baseline differences between treatment interventions, and those in which major differences occurred at a rate
of > 1 per 20 comparisons (which makes them unlikely to have occurred by chance) (Carlisle 2015; Carlisle 2017). When we had
concerns about study methods, we excluded the study if study authors did not respond to our requests for clariﬁcation.
3. Using odds ratio instead of Peto odds ratio: The Cochrane Handbook for Systematic Reviews of Interventions discourages use of the
Peto odds ratio and recommends use of the odds ratio instead (Higgins 2011).
4. Summary of ﬁndings tables: We prepared these in accordance with new requirements provided in the Cochrane Handbook for
Systematic Reviews of Interventions.
5. Search for ongoing trials: The protocol and the original review did not plan or perform this.
6. Remove “in adults” from title: The protocol did not attempt to include adults only, and the original review included only one
study in children (Greco 1982).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Adenosine [adverse effects; ∗therapeutic use]; Anti-Arrhythmia Agents [adverse effects; ∗therapeutic use]; Calcium Channel Blockers
[adverse effects; ∗therapeutic use]; Randomized Controlled Trials as Topic; Tachycardia, Supraventricular [∗drug therapy]; Verapamil
[adverse effects; therapeutic use]
MeSH check words
Adult; Humans
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